Clinical evaluation of BD VeritorTMSARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia®2 SARS Antigen point-of-care test
Detection Principle
ImmunoAssay-Antigen
Target
Not specified
Testing Method Category
Testing Method
kit
Testing Method - Additional Info
BD Veritor™ System for Rapid Detection of SARS-CoV-2 nucleocapsid antigen (Veritor) compared to Lyra PCR and to Sofia2 antigen test
Reported Performance
PPA: 81.8%-87.5% (Veritor vs Lyra),97.4% (Veritor vs Sofia2); NPA: 98.1% (Veritor vs Sofia2); OPA: 98.1% (Veritor vs Sofia2)
Sample Size
251 (vs Lyra) & 361 (vs Sofia2) patients
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements